Your Product Was Named in a Philippine FDA Public Advisory and the Platform Wants It Delisted: What to Do, in Order

Step one, verify: is the advisory real and is it about your goods?

Verify two things: that the advisory really appears on the official FDA publication channel, and that the product it describes is the one you sell. The two answers decide your route.

Authenticity matters because forged "advisory" screenshots are used to extort sellers, and competitors sometimes wave an old advisory or one about a different product to scare you into delisting. Go to the advisories section of the official FDA website and search by product name, brand or advisory number for the original text instead of relying on a forwarded image. If a platform takedown notice quotes an advisory number, use it to find the original. If you cannot find one, ask the platform in writing for the document it relied on.

To confirm the product, compare each detail in the advisory: brand, product name, size, the packaging shown and the manufacturer or importer named on the label. Four outcomes are possible. One, it is the product you import and sell, and you do not hold the required registration or notification. Two, the brand is yours but the unit photographed was not imported by you. It is a parallel import brought in by someone else. Three, it is a counterfeit that resembles your packaging. Four, your product is registered, but the advisory concerns another size or batch, or your registration does not match the packaging actually on sale.

Responsibility and remedy differ sharply across the four. In the first you have work to do. In the second and third you are also a victim and need to explain to the FDA with evidence. In the fourth you need to check the scope of your registration. Until this is settled, issue no public statement and do not argue on social media. Stopping sales, however, does not wait for verification. If the advisory appears to point at something you sell, stop first.

Identify the type of advisory as well. A warning to the public not to buy or use an unregistered product is the most common kind. Another kind concerns a harmful ingredient, a false health claim or a safety problem. That is more serious, often comes with a recall requirement and has to be handled faster.

Step two, stop and quarantine: every channel at once, stock untouched

While you verify, stop selling the named product on every channel and set the stock aside under quarantine. The faster and more completely this is done, the stronger your position later.

Cover every channel: each listing and each shop on the marketplaces, posts and live-selling showcases on social media, shelves in physical stores, and stock held by distributors and agents. Platforms usually remove the listing themselves and send a notice. Your job is to cooperate, not to relist. Send distributors a written instruction to stop selling at once and report their quantities, and keep their replies.

Three things must not happen. Do not carry on under a new link, a new name or a new main image. Platforms and regulators can both detect it, and continued sale after an advisory carries far heavier consequences than the lack of registration did. Do not dump the stock cheaply on someone else. Liability does not travel with the goods, and you gain a downstream buyer who will point back at you. Do not strip labels, repack or destroy. The stock is your basis for explaining, for registering or for disposal under procedure, and destroying it yourself may look like destroying evidence and ends any chance of returning it to the supplier.

To quarantine, move the named product out of the saleable area, store it separately under lock and mark it "on hold". Count and record product name, size, batch number, quantity and location. Gather the purchase documents, import papers, supplier information and sales records in one place. For units already sold, estimate quantities, period and channels, which is the starting point for deciding whether a recall is needed where safety is involved.

Use the occasion to check the registration status of other products in the same category or from the same supplier. Often only one is named while the rest are in exactly the same position. Where you find a problem, taking the product down yourself is better than waiting for the next advisory. For complaints and recalls arising from product quality see handling a product complaint or recall demand.

Step three, handle by situation: unregistered, parallel import or counterfeit

Three situations call for three responses, and the key in each is evidence showing where you stand.

Situation one: you import and sell the product, and you do not hold the authorisation. This is the most direct case. There is nothing to argue and the way out is to regularise. To sell food, food supplements, cosmetics, medicines, medical devices or household hazardous substances in the Philippines, the business must hold an FDA licence to operate for the activity, and the product itself must be registered or notified according to its category. Both are required, and until they are in place this stock cannot be sold. The path differs by category: for cosmetics see FDA notification for cosmetics, and for supplements see registering a food supplement with the FDA.

Situation two: the brand is yours and the named goods are parallel imports. You are the brand owner or authorised distributor and your product is registered, but someone has bypassed you, bought in another country and sold locally, perhaps with packaging, labelling or a formula different from the locally registered version. Write to the FDA explaining which version is imported by you and registered and how it can be told apart by packaging, label and batch number, and enclose your registration and import records. Notify the platform as well and ask it to distinguish by product features so that your compliant listing is not removed together with the others.

Situation three: counterfeiting. The unit shown is a fake. You again explain to the FDA and submit a comparison of genuine and counterfeit goods, and you separately pursue the source through intellectual property and platform complaint routes.

In the last two situations the advisory has hurt your brand too, and wanting to clear your name quickly is understandable. The order should still be a written explanation with evidence to the regulator first and outside communication second, with the public wording matching what you filed.

One further situation is easy to miss. Your product is registered, but the packaging, label or claims on sale differ from what was registered, for instance a new size, an added benefit claim or a label missing required information. A regulator may treat that as an unapproved change, and you must either return to the registered version or file the variation. Labelling requirements are in product labelling rules in the Philippines.

Dealing with the stock: four exits, chosen by whether registration is achievable

What happens to the stock depends on one question: can this product be registered within a reasonable time? If it can, hold it under quarantine. If it cannot, consider return or disposal under procedure.

Exit one is to hold the stock while you regularise. The product meets Philippine requirements and only the paperwork is missing, so keep it sealed while the application runs. Watch the shelf life, since registration takes time and food or cosmetics that will be near expiry before approval are not worth waiting for. Check also whether the labels on this stock match the registration once it is granted. If they do not, they must be corrected as required before sale.

Exit two is return to the supplier. The product cannot be registered here, for example because it contains an ingredient not permitted locally or the supplier cannot provide the technical documents needed. Negotiate a return or a re-export. Whether that is possible and who pays depends on the purchase contract and on what was agreed about regulatory responsibility. It is also a reminder to write into future contracts that the supplier must provide registration documents, and how losses are shared if the product cannot be registered.

Exit three is another lawful use. Occasionally goods can be shipped on to a market where they may be sold. That involves export formalities and the rules of the destination and is not a matter of simply posting them away.

Exit four is disposal under procedure. Where the goods can be neither registered nor returned, deal with them as the regulator requires, which may include destruction under supervision. Destruction needs records and proof, so do not throw the goods away quietly.

If FDA officers have already sealed the goods or issued a disposal directive, the outcome is not yours alone to decide. Follow the directive and reply in writing within the period given. If the goods are still at the port and not yet cleared, a customs layer is added. See what to do when customs holds your cargo.

In your accounts, collect the purchase cost, disposal expenses and likely loss for this stock separately and keep every voucher. You will need them to recover from the supplier or to explain an inventory loss to the tax authority later. Leave a written record of every step of the disposal: quantity, destination, person responsible and date.

What to tell the platform, customers and the regulator: three written pieces

After an advisory, communication should be truthful, in writing and consistent, addressed to three audiences.

The platform. A marketplace that receives an advisory removes the listing and may also deduct points, restrict shop functions or delay payouts. File an explanation through its appeal channel stating that sales of the product have stopped, what the situation is, whether registration pending, parallel import or counterfeit, and the compliance documents for your other products. For a product that really is unregistered, do not appeal for reinstatement. The purpose of the appeal is to keep the whole shop from being penalised. Once registration is granted, apply to relist with the proof. For a frozen shop or withheld payout see what to do when a seller account is frozen.

Customers and channels. Distributors, agents and large customers should receive a short written notice saying which product and batches are suspended, that the reason is a regulatory formality being completed, that they should stop selling and report their stock, and that further instructions will follow. For end consumers who have already bought, where the advisory concerns registration and not safety you generally need not contact each one, but prepare a standard reply and handle return and refund requests in line with consumer protection requirements. Where safety is involved, notify proactively as a recall requires.

The regulator. If you receive a written notice, a summons or a request for explanation from the FDA, you must reply in writing within the period stated, setting out the facts, the steps already taken and your corrective plan, with evidence attached. If nothing has been addressed to you and your product simply appears in a public advisory, you may still write on your own initiative, particularly in the parallel import and counterfeit situations.

On whether the advisory itself can be updated or taken down: once the product is registered, whether and how an earlier advisory is updated is for the FDA to decide and does not follow automatically from an application. What you can do after registration is show the proof to the platform and to customers. Do not announce that "the FDA has cleared us" or anything similar without a document behind it, and do not accuse the advisory of being wrong unless you hold a written conclusion from the regulator.

Not being named again: three checks before listing, and how Yixing can help

The root cause of an advisory is almost always the same: the product went on sale first, and the paperwork came later or never. Reverse the order and the problem does not arise.

Run three checks before listing. First, classify. Establish whether the product counts in the Philippines as food, a food supplement, a cosmetic, a medicine, a medical device or another regulated category. Classification can differ between countries, and benefit claims can change it. Second, confirm both authorisations. Does the business hold a licence to operate covering the activity, whether import, distribution or retail? Has the product completed the registration or notification for its category, who holds it, and do the registered size, packaging and label match what you intend to sell? When buying from someone else, ask to see the registration and confirm it on the official channel. Third, check the claims. The benefits stated on the listing, the packaging and in advertising must stay within what was registered, above all anything about treating or preventing disease.

A licence to operate also expires, and letting it lapse puts products already on sale at risk. Renewal is covered in renewing an FDA licence to operate.

Yixing Travel Consultancy (SEC Registration No. CS202009551, Bureau of Immigration Accredited Agency No. CA-202624381-1) provides compliance retainer services and product access support to foreign-owned businesses in the Philippines: verifying the original advisory and the product it describes, organising the records of the sales stop and the quarantined stock, preparing the document list for an explanation to the regulator, following up the licence to operate and product registration, and helping draft the written notices to platforms and channels. We are a private consultancy with no affiliation to any government agency. We neither represent nor can influence a decision of the FDA, and we are not a law firm. Whether a product can be registered and whether an advisory is updated are decisions of the regulator. If your product has just been named, stop selling and quarantine the stock, then contact us with the original advisory, your purchase documents and the licences you already hold. For your specific case consult a licensed lawyer; this article is not legal advice.